Connexins and atrial fibrillation: Filling in the gaps

Circulation

Volumn 125, Issue 2, 2012, Pages 203-206

  Kato, Takeshi ^a   Iwasaki, Yu Ki ^a   Nattel, Stanley ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

antiarrhythmia agents; arrhythmia (mechanisms); atrial fibrillation; Editorials; gene expression; gene therapy

Indexed keywords

ADENOVIRUS VECTOR; CONNEXIN 30; CONNEXIN 30.2; CONNEXIN 31.9; CONNEXIN 37; CONNEXIN 40; CONNEXIN 43; CONNEXIN 45; GAP JUNCTION PROTEIN; UNCLASSIFIED DRUG;

CORONARY ARTERY DISEASE; DRUG EFFICACY; GAP JUNCTION; HEART ATRIUM FIBRILLATION; HEART MUSCLE POTENTIAL; HUMAN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ATRIAL FIBRILLATION; CONNEXIN 43; CONNEXINS; HEART CONDUCTION SYSTEM;

EID: 84856105635     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.075432     Document Type: Review

References (44)

1. Dobrev D, Nattel S. New drugs for treatment of atrial fibrillation. Lancet. 2010;375:1212-1223.
2. Wakili R, Voigt N, Kääb S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011;121: 2955-2968.
3. Spach MS, Starmer CF. Altering the topology of gap junctions a major therapeutic target for atrial fibrillation. Cardiovasc Res. 1995;30: 337-344.
4. Tribulová N, Knezl V, Okruhlicová L, Slezák J. Myocardial gap junctions: Targets for novel approaches in the prevention of life-threatening cardiac arrhythmias. Physiol Res. 2008;57(suppl 2):S1-S13.
5. Saffitz JE, Douglas P. Zipes lecture: Biology and pathobiology of cardiac connexins: From cell to bedside. Heart Rhythm. 2006;3:102-107. (Pubitemid 43071901)
6. Solan JL, Lampe PD. Connexin43 phosphorylation: Structural changes and biological effects. Biochem J. 2009;419:261-272.
7. Gollob MH, Jones DL, Krahn AD, Danis L, Gong XQ, Shao Q, Liu X, Veinot JP, Tang AS, Stewart AF, Tesson F, Klein GJ, Yee R, Skanes AC, Guiraudon GM, Ebihara L, Bai D. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med. 2006;354:2677-2688.
8. Firouzi M, Ramanna H, Kok B, Jongsma HJ, Koeleman BP, Doevendans PA, Groenewegen WA, Hauer RN. Association of human connexin40 gene polymorphisms with atrial vulnerability as a risk factor for idiopathic atrial fibrillation. Circ Res. 2004;95:e29-e33.
9. Juang JM, Chern YR, Tsai CT, Chiang FT, Lin JL, Hwang JJ, Hsu KL, Tseng CD, Tseng YZ, Lai LP. The association of human connexin 40 genetic polymorphisms with atrial fibrillation. Int J Cardiol. 2007;116:107-112.
10. Wirka RC, Gore S, Van Wagoner DR, Arking DE, Lubitz SA, Lunetta KL, Benjamin EJ, Alonso A, Ellinor PT, Barnard J, Chung MK, Smith JD. A common connexin-40 gene promoter variant affects connexin-40 expression in human atria and is associated with atrial fibrillation. Circ Arrhythm Electrophysiol. 2011;4:87-93.
11. Elvan A, Huang XD, Pressler ML, Zipes DP. Radiofrequency catheter ablation of the atria eliminates pacing-induced sustained atrial fibrillation and reduces connexin 43 in dogs. Circulation. 1997;96:1675-1685. (Pubitemid 27375369)
12. van der Velden HM, van Kempen MJ, Wijffels MC, van Zijverden M, Groenewegen WA, Allessie MA, Jongsma HJ. Altered pattern of connexin40 distribution in persistent atrial fibrillation in the goat. J Cardiovasc Electrophysiol. 1998;9:596-607. (Pubitemid 128721719)
13. van der Velden HM, Ausma J, Rook MB, Hellemons AJ, van Veen TA, Allessie MA, Jongsma HJ. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res. 2000;46:476-486. (Pubitemid 30319333)
14. Haugan K, Miyamoto T, Takeishi Y, Kubota I, Nakayama J, Shimojo H, Hirose M. Rotigaptide (ZP123) improves atrial conduction slowing in chronic volume overload-induced dilated atria. Basic Clin Pharmacol Toxicol. 2006;99:71-79. (Pubitemid 44034398)
15. Ryu K, Li L, Khrestian CM, Matsumoto N, Sahadevan J, Ruehr ML, Van Wagoner DR, Efimov IR, Waldo AL. Effects of sterile pericarditis on connexins 40 and 43 in the atria: Correlation with abnormal conduction and atrial arrhythmias. Am J Physiol. 2007;293:H1231-H1241. (Pubitemid 47254226)
16. Sawaya SE, Rajawat YS, Rami TG, Szalai G, Price RL, Sivasubramanian N, Mann DL, Khoury DS. Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. Am J Physiol. 2007;292:H1561-H1567. (Pubitemid 46377145)
17. Burstein B, Comtois P, Michael G, Nishida K, Villeneuve L, Yeh YH, Nattel S. Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res. 2009;105:1213-1222.
18. Hoyano M, Ito M, Kimura S, Tanaka K, Okamura K, Komura S, Mitsuma W, Hirono S, Chinushi M, Kodama M, Aizawa Y. Inducibility of atrial fibrillation depends not on inflammation but on atrial structural remodeling in rat experimental autoimmune myocarditis. Cardiovasc Pathol. 2010;19:e149-e157.
19. Reil JC, Hohl M, Selejan S, Lipp P, Drautz F, Kazakow A, Münz BM, Ml̈ler P, Steendijk P, Reil GH, Allessie MA, Böhm M, Neuberger HR. Aldosterone promotes atrial fibrillation [published online ahead of print August 4, 2011]. Eur Heart J.
20. Bikou O, Thomas D, Trappe K, Lugenbiel P, Kelemen K, Koch M, Soucek R, Voss F, Becker R, Katus HA, Bauer A. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res. 2011;92:218-225.
21. Xiao P, Gao C, Fan J, Du H, Long Y, Yin Y. Blockade of angiotensin II improves hyperthyroid induced abnormal atrial electrophysiological properties. Regul Pept. 2011;169:31-38.
22. Kim SJ, Choisy SC, Barman P, Zhang H, Hancox JC, Jones SA, James AF. Atrial remodeling and the substrate for atrial fibrillation in rat hearts with elevated afterload. Circ Arrhythm Electrophysiol. 2011;4:761-769.
23. Dupont E, Ko Y, Rothery S, Coppen SR, Baghai M, Haw M, Severs NJ. The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation. Circulation. 2001;103:842-849. (Pubitemid 32163883)
24. Polontchouk L, Haefliger JA, Ebelt B, Schaefer T, Stuhlmann D, Mehlhorn U, Kuhn-Regnier F, De Vivie ER, Dhein S. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol. 2001;38:883-891. (Pubitemid 32835768)
25. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res. 2002;54:361-379. (Pubitemid 34327915)
26. Nao T, Ohkusa T, Hisamatsu Y, Inoue N, Matsumoto T, Yamada J, Shimizu A, Yoshiga Y, Yamagata T, Kobayashi S, Yano M, Hamano K, Matsuzaki M. Comparison of expression of connexin in right atrial myocardium in patients with chronic atrial fibrillation versus those in sinus rhythm. Am J Cardiol. 2003;91:678-683. (Pubitemid 36287457)
27. Kanagaratnam P, Cherian A, Stanbridge RD, Glenville B, Severs NJ, Peters NS. Relationship between connexins and atrial activation during human atrial fibrillation. J Cardiovasc Electrophysiol. 2004;15:206-216.
28. Wetzel U, Boldt A, Lauschke J, Weigl J, Schirdewahn P, Dorszewski A, Doll N, Hindricks G, Dhein S, Kottkamp H. Expression of connexins 40 and 43 in human left atrium in atrial fibrillation of different aetiologies. Heart. 2005;91:166-170.
29. Wilhelm M, Kirste W, Kuly S, Amann K, Neuhuber W, Weyand M, Daniel WG, Garlichs C. Atrial distribution of connexin 40 and 43 in patients with intermittent, persistent, and postoperative atrial fibrillation. Heart Lung Circ. 2006;15:30-37. (Pubitemid 43355904)
30. Takeuchi S, Akita T, Takagishi Y, Watanabe E, Sasano C, Honjo H, Kodama I. Disorganization of gap junction distribution in dilated atria of patients with chronic atrial fibrillation. Circ J. 2006;70:575-582.
31. Rucker-Martin C, Milliez P, Tan S, Decrouy X, Recouvreur M, Vranckx R, Delcayre C, Renaud JF, Dunia I, Segretain D, Hatem SN. Chronic hemodynamic overload of the atria is an important factor for gap junction remodeling in human and rat hearts. Cardiovasc Res. 2006;72:69-79. (Pubitemid 44310634)
32. 2+ in gap-junction remodeling: Studies in humans and rats. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:125-138.
33. Li JY, Lai YJ, Yeh HI, Chen CL, Sun S, Wu SJ, Lin FY. Atrial gap junctions, NF-kappaB and fibrosis in patients undergoing coronary artery bypass surgery: The relationship with postoperative atrial fibrillation. Cardiology. 2009;112:81-88.
34. Girmatsion Z, Biliczki P, Bonauer A, Wimmer-Greinecker G, Scherer M, Moritz A, Bukowska A, Goette A, Nattel S, Hohnloser SH, Ehrlich JR. Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm. 2009;6:1802-1809.
35. Adam O, Lavall D, Theobald K, Hohl M, Grube M, Ameling S, Sussman MA, Rosenkranz S, Kroemer HK, Schäfers HJ, Böhm M, Laufs U. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol. 2010;55:469-480.
36. Hagendorff A, Schumacher B, Kirchhoff S, Lüderitz B, Willecke K. Conduction disturbances and increased atrial vulnerability in connexin40- deficient mice analyzed by transesophageal stimulation. Circulation. 1999;99:1508-1515. (Pubitemid 29140919)
37. Tuomi JM, Tyml K, Jones DL. Atrial tachycardia/fibrillation in the connexin 43 G60S mutant (oculodentodigital dysplasia) mouse. Am J Physiol. 2011;300:H1402-H1411.
38. Beauchamp P, Yamada KA, Baertschi AJ, Green K, Kanter EM, Saffitz JE, Kléber AG. Relative contributions of connexins 40 and 43 to atrial impulse propagation in synthetic strands of neonatal and fetal murine cardiomyocytes. Circ Res. 2006;99:1216-1224. (Pubitemid 44808658)
39. Guerra JM, Everett TH, Lee KW, Wilson E, Olgin JE. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation. 2006;114:110-118. (Pubitemid 44420742)
40. Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan JK, Nattel S. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation. 2007;115:310-318. (Pubitemid 46151658)
41. Laurent G, Leong-Poi H, Mangat I, Moe GW, Hu X, So PP, Tarulli E, Ramadeen A, Rossman EI, Hennan JK, Dorian P. Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs. Circ Arrhythm Electrophysiol. 2009;2:171-178.
42. Igarashi T, Finet JE, Takeuchi A, Fujino Y, Strom M, Greener ID, Rosenbaum DS, Donahue JK. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation. 2012;125:216-225.
43. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: Mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1:62-73.
44. Nattel S. From guidelines to bench: Implications of unresolved clinical issues for basic investigations of atrial fibrillation mechanisms. Can J Cardiol. 2011;27:19-26.